Vaxcyte (PCVX) Shares Outstanding (2019 - 2026)

Vaxcyte (PCVX) has 8 years of Shares Outstanding data on file, last reported at $144.3 million in Q1 2026.

• Shares Outstanding for Q1 2026 came in at $144.3 million, up 11.92% year-over-year; the trailing twelve-month figure through Mar 2026 was $144.3 million (up 11.92% YoY), and the FY2025 annual result was $131.1 million, up 4.94% from the prior year.
• Shares Outstanding advanced to $144.3 million in Q1 2026 per PCVX's latest filing, from $131.1 million in the prior quarter.
• Over five years, Shares Outstanding peaked at $144.3 million in Q1 2026 and troughed at $56.5 million in Q1 2022.
• A 5-year average of $103.1 million and a median of $108.8 million in 2024 frame the typical range for Shares Outstanding.
• The sharpest annual moves came in 2023 and 2025: Shares Outstanding soared 60.02% in 2023, then grew 4.5% in 2025.
• A 5-year view of Shares Outstanding shows it stood at $79.5 million in 2022, then advanced by 20.0% to $95.4 million in 2023, then soared by 30.96% to $124.9 million in 2024, then rose by 4.94% to $131.1 million in 2025, then climbed by 10.11% to $144.3 million in 2026.
• Business Quant data shows PCVX's Shares Outstanding at $144.3 million in Q1 2026, $131.1 million in Q4 2025, and $130.0 million in Q3 2025.